Zobrazeno 1 - 10
of 880
pro vyhledávání: ''
Autor:
Jitsuo Usuda, Susumu Takeuchi, Kengo Nagashima, Noriko Motoi, Masahiro Seike, Jun Matsubayashi, Hideaki Shiraishi, Kazufumi Honda, Shun-ichi Watanabe, Rintaro Noro, Kaoru Kubota, Xue Meng, Tatsuya Inoue, Huang Wilber, Ayumi Kashiro, Tetsuya Okano, Yukihiro Yoshida, Shinobu Kunugi, Akihiko Gemma, Norihiko Ikeda
Publikováno v:
Cancer Science. 113:1002-1009
Although adjuvant tegafur/uracil (UFT) is recommended for patients with completely resected stage I non-small cell lung cancer (NSCLC) in Japan, only one-third of cases has received adjuvant chemotherapy according to real-world data. Therefore, robus
Autor:
Jeong Eun Kim, Su Han Cho, Tae Won Kim, Sun Young Kim, Eunyoung Tak, Sung-Min Chun, Yong Sang Hong, Kwoneel Kim
Publikováno v:
Cancer Genetics. :27-36
Recurrent gene mutations and copy number alterations in cancer patients are presumably associated with resistance to targeted therapy. In the present study, we assessed the gene mutations and copy number alterations that recurrently occurred in cetux
Autor:
Kimihiro Yamashita, Junko Mukohyama, Tetsu Nakamura, Gosuke Takiguchi, Kouta Yamada, Kyosuke Agawa, Shingo Kanaji, Mitsugu Fujita, Taro Oshikiri, Yoshihiro Kakeji, Satoshi Suzuki, Masafumi Saito, Hiroshi Hasegawa, Naoki Urakawa, Akihiro Watanabe, Takeru Matsuda, Akio Nakagawa
Publikováno v:
Anticancer Research. 41:4117-4126
Background/aim Cancer stem cells (CSCs) contribute to resistance against neoadjuvant chemotherapy (NAC) in esophageal squamous cell carcinoma (ESCC). We conducted a retrospective observational study for the relationship between the expression levels
Autor:
Todd C. Knepper, Robyn A Panchaud, Nikhil I. Khushalani, Elnara Muradova, Andrew S. Brohl, Leah Cohen, Kenneth Y. Tsai, James A. DeCaprio
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 17, Pp 5889-5896 (2021)
Cancer Medicine, Vol 10, Iss 17, Pp 5889-5896 (2021)
Background The use of targeted therapy remains a treatment consideration for some patients with advanced Merkel cell carcinoma (MCC). However, supportive data on the use of targeted therapy approaches are limited. Thus, we sought to evaluate the resp
Autor:
Dooreh Kim, Jee Ye Kim, Byeong Woo Park, Seung Il Kim, Joon Jeong, Soong June Bae, Janghee Lee, Chihwan Cha, Hyung Seok Park, Soeun Park, Seho Park, Sung Gwe Ahn
Publikováno v:
International Journal of Cancer
Incorporating dual human epidermal growth factor receptor 2 (HER2) blockade into neoadjuvant systemic therapy (NST) led to higher response in patients with HER2‐positive breast cancer. However, axillary response to treatment regimens, including sin
Autor:
Josef Vodicka, Gabriela Krakorova, Jiri Blazek, Zuzana Teufelova, Magda Barinova, Karolina Hurdalkova, Marcela Buresova, Martin Svaton, Ondrej Topolcan, Miloš Pešek
Publikováno v:
Anticancer Research. 41:2053-2058
Aim To investigate potential associations between selected oncomarkers [carcinoembryonic antigen (CEA), C-terminus of cytokeratin 19 (CYFRA 21-1, CYFRA), and squamous cell carcinoma antigen (SCC)] and outcomes in patients with NSCLC treated with beva
Autor:
Shigeo Hisamori, Shigeru Tsunoda, Yasunori Deguchi, Hiroaki Hata, Dai Manaka, Yoshio Kadokawa, Yoshiharu Sakai, Kazutaka Obama, Hiroshi Okabe, Seiichiro Kanaya, Tatsuto Nishigori, Sachiko Minamiguchi, Daiju Yokoyama
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports
Scientific Reports
IntroductionPoor Trastuzumab (Tmab) response in human epidermal growth factor receptor 2-overexpressing gastric or gastroesophageal junction adenocarcinoma (HER2-GEA) is reported to be associated with loss of phosphatase and tensin homolog (PTEN) exp
Autor:
Miyako Satouchi, Noriyuki Masuda, Toshinori Soejima, Hideyuki Harada, Masahiro Tanaka, Makoto Nishio, Isamu Okamoto, Takuyo Kozuka, Takashi Seto, Hiroshi Tsubouchi, Yasuyuki Kakurai, Koji Takeda, Tomonari Sasaki, Yasumasa Nishimura, Kazushige Hayakawa, Kazuhiko Nakagawa, Nobuyuki Yamamoto
Publikováno v:
Clinical Lung Cancer. 22:134-141
Background We evaluated the tolerability and efficacy of nimotuzumab, a humanized IgG1 monoclonal anti–epidermal growth factor receptor antibody, with concurrent chemoradiotherapy in patients with unresectable locally advanced non–small-cell lung
Autor:
Tetsuji Takayama, Ajay Goel, Kensuke Yamamura, Yasuyuki Okada, Satoshi Nishiwada, Hideo Baba, Masayuki Sho
Publikováno v:
Eur J Cancer
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. While the extracellular matrix component plays an integral role in PDAC pathogenesis and mediating chemoresistance, its role in predicting response to chemotherapy in pat
Autor:
Chiara Cremolini, Axel Grothey, Jim Abraham, Donald A. Berry, David D. Halbert, Mohamed E. Salem, Michael J. Hall, Matthew J. Oberley, Anthony Helmstetter, Carlotta Antoniotti, W. Michael Korn, Anthony F. Shields, David Spetzler, John L. Marshall, Alfredo Falcone, Phillip Stafford, Daniel Magee, Joanne Xiu, Heinz-Josef Lenz, Alan P. Venook
Publikováno v:
Clinical Cancer Research. 27:1174-1183
Purpose: FOLFOX, FOLFIRI, or FOLFOXIRI chemotherapy with bevacizumab is considered standard first-line treatment option for patients with metastatic colorectal cancer (mCRC). We developed and validated a molecular signature predictive of efficacy of